Intra-Cellular Shares May Double on Bipolar Depression Data
This article is for subscribers only.
Intra-Cellular Therapies Inc. shares could double if the company shows positive data in a pair of late-stage studies in bipolar depression next week, according to two analysts.
Wall Street will want to see both trials reach their main goal of improving depression symptoms for shares to move higher, Cowen analyst Ritu Baral wrote in a July 1 note. She pegs the chance of succeeding at just over 50% for each study. Baral predicts shares could at least double if both studies succeed, but an investor survey suggests the stock may fall as much as 15% if only one does, she said. Both studies failing may send shares down 50% or more, she said.